- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06261957
Studie k posouzení a porovnání bezpečnosti a snášenlivosti 3měsíční léčby salbutamolem podávaným prostřednictvím MDI obsahující hnací plyn HFA-152a nebo HFA-134a u účastníků ve věku 12 let a starších s astmatem
Randomizovaná, dvojitě zaslepená, paralelní skupinová, multicentrická studie k vyhodnocení dlouhodobé bezpečnosti salbutamolu jako záchranné medikace při podávání prostřednictvím inhalátorů s odměřenými dávkami obsahujícími hnací látku HFA-152a nebo referenční HFA-134a
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
-
Buenos Aires, Argentina, C1425BEN
- GSK Investigational Site
-
Buenos Aires, Argentina, C1426ABP
- GSK Investigational Site
-
Buenos Aires, Argentina, C1425AZE
- GSK Investigational Site
-
La Plata, Argentina, 1900
- GSK Investigational Site
-
Mendoza, Argentina, M5500CCG
- GSK Investigational Site
-
-
-
-
New South Wales
-
Botany, New South Wales, Austrálie, 2019
- GSK Investigational Site
-
Coffs Harbour, New South Wales, Austrálie, 2450
- GSK Investigational Site
-
Kanwal, New South Wales, Austrálie, 2259
- GSK Investigational Site
-
-
Western Australia
-
Spearwood, Western Australia, Austrálie, 6163
- GSK Investigational Site
-
-
-
-
-
Iloilo City, Filipíny, 5000
- GSK Investigational Site
-
-
-
-
-
Amiens, Francie, 80054
- GSK Investigational Site
-
Argenteuil, Francie, 95100
- GSK Investigational Site
-
Créteil, Francie, 94010
- GSK Investigational Site
-
Poitiers, Francie, 86021
- GSK Investigational Site
-
Pontoise, Francie, 95303
- GSK Investigational Site
-
Strasbourg, Francie, 67091
- GSK Investigational Site
-
-
-
-
-
Cagliari, Itálie, 09042
- GSK Investigational Site
-
Florence, Itálie, 50134
- GSK Investigational Site
-
Foggia, Itálie, 71100
- GSK Investigational Site
-
Milan, Itálie, 20162
- GSK Investigational Site
-
Naples, Itálie, 80131
- GSK Investigational Site
-
Padova, Itálie, 35128
- GSK Investigational Site
-
Torino, Itálie, 10128
- GSK Investigational Site
-
Tradate VA, Itálie, 21100
- GSK Investigational Site
-
Verona, Itálie, 37134
- GSK Investigational Site
-
-
RM
-
Roma, RM, Itálie, 00161
- GSK Investigational Site
-
-
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S 2J5
- GSK Investigational Site
-
Brampton, Ontario, Kanada, L6T 0G1
- GSK Investigational Site
-
Ottawa, Ontario, Kanada, K1H 1E4
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M9V 4B4
- GSK Investigational Site
-
Windsor, Ontario, Kanada, N8X 2G1
- GSK Investigational Site
-
-
Quebec
-
Québec, Quebec, Kanada, G1V 4W2
- GSK Investigational Site
-
Québec, Quebec, Kanada, G1W 4R4
- GSK Investigational Site
-
-
-
-
-
Panama City, Panama
- GSK Investigational Site
-
Panama City, Panama, 7099
- GSK Investigational Site
-
Panama City, Panama, 7002
- GSK Investigational Site
-
-
-
-
-
Bialystok, Polsko, 15-010
- GSK Investigational Site
-
Bielsko-Biala, Polsko, 43-300
- GSK Investigational Site
-
Chorzów, Polsko, 41-500
- GSK Investigational Site
-
Elblag, Polsko, 82-300
- GSK Investigational Site
-
Katowice, Polsko, 40-600
- GSK Investigational Site
-
Ostrowiec Świętokrzyski, Polsko, 27-400
- GSK Investigational Site
-
Płock, Polsko, 09-407
- GSK Investigational Site
-
Tarnów, Polsko, 33-100
- GSK Investigational Site
-
-
-
-
-
Bebington, Spojené království, CH63 9JP
- GSK Investigational Site
-
Cambridgeshire, Spojené království, CB7 5JD
- GSK Investigational Site
-
Corby, Spojené království, NN17 2UR
- GSK Investigational Site
-
Greater Manchester, Spojené království, OL6 6HD
- GSK Investigational Site
-
Guisborough, Spojené království, TS14 7DJ
- GSK Investigational Site
-
Hounslow, Spojené království, TW3 3EL
- GSK Investigational Site
-
Rhyl, Spojené království, LL18 4HZ
- GSK Investigational Site
-
Uttoxeter, Spojené království, ST14 5JX
- GSK Investigational Site
-
-
-
-
California
-
North Hollywood, California, Spojené státy, 91606-3287
- GSK Investigational Site
-
San Mateo, California, Spojené státy, 94403
- GSK Investigational Site
-
-
Florida
-
Aventura, Florida, Spojené státy, 33180
- GSK Investigational Site
-
Clearwater, Florida, Spojené státy, 33756
- GSK Investigational Site
-
DeLand, Florida, Spojené státy, 32720
- GSK Investigational Site
-
Miami, Florida, Spojené státy, 33173
- GSK Investigational Site
-
Miami, Florida, Spojené státy, 33144
- GSK Investigational Site
-
Miami, Florida, Spojené státy, 33155
- GSK Investigational Site
-
Naples, Florida, Spojené státy, 34102
- GSK Investigational Site
-
Plantation, Florida, Spojené státy, 33317
- GSK Investigational Site
-
Winter Park, Florida, Spojené státy, 32789-3385
- GSK Investigational Site
-
-
Georgia
-
Rincon, Georgia, Spojené státy, 31326-5131
- GSK Investigational Site
-
Stonecrest, Georgia, Spojené státy, 30038
- GSK Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy, 40217
- GSK Investigational Site
-
Owensboro, Kentucky, Spojené státy, 42301
- GSK Investigational Site
-
-
Massachusetts
-
Fall River, Massachusetts, Spojené státy, 02723-1511
- GSK Investigational Site
-
-
Minnesota
-
Minneapolis, Minnesota, Spojené státy, 55402-2508
- GSK Investigational Site
-
Minneota, Minnesota, Spojené státy, 56001
- GSK Investigational Site
-
-
Mississippi
-
Olive Branch, Mississippi, Spojené státy, 38654
- GSK Investigational Site
-
-
Missouri
-
Columbia, Missouri, Spojené státy, 65203
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Spojené státy, 89052-5015
- GSK Investigational Site
-
-
New Jersey
-
Jersey City, New Jersey, Spojené státy, 07306
- GSK Investigational Site
-
Riverdale, New Jersey, Spojené státy, 07457
- GSK Investigational Site
-
-
New York
-
Brooklyn, New York, Spojené státy, 11220
- GSK Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, Spojené státy, 28803
- GSK Investigational Site
-
Winston-Salem, North Carolina, Spojené státy, 27104
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45231
- GSK Investigational Site
-
Dublin, Ohio, Spojené státy, 43016
- GSK Investigational Site
-
-
Oregon
-
Medford, Oregon, Spojené státy, 97504
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Spojené státy, 15241
- GSK Investigational Site
-
Pottstown, Pennsylvania, Spojené státy, 19464-3241
- GSK Investigational Site
-
-
South Carolina
-
Rock Hill, South Carolina, Spojené státy, 29732
- GSK Investigational Site
-
Spartanburg, South Carolina, Spojené státy, 29303
- GSK Investigational Site
-
Spartanburg, South Carolina, Spojené státy, 29303-4225
- GSK Investigational Site
-
Union, South Carolina, Spojené státy, 29379-7409
- GSK Investigational Site
-
-
Texas
-
Sugar Land, Texas, Spojené státy, 77479
- GSK Investigational Site
-
Tomball, Texas, Spojené státy, 77375-3332
- GSK Investigational Site
-
-
-
-
-
Pathum Thani, Thajsko, 12120
- GSK Investigational Site
-
-
-
-
-
Athens, Řecko, 15669
- GSK Investigational Site
-
Larissa, Řecko, 41110
- GSK Investigational Site
-
Thessaloniki, Řecko, 57010
- GSK Investigational Site
-
-
-
-
-
Barcelona, Španělsko, 08017
- GSK Investigational Site
-
Barcelona, Španělsko, 08540
- GSK Investigational Site
-
Benalmádena, Španělsko, 29631
- GSK Investigational Site
-
Madrid, Španělsko, 28041
- GSK Investigational Site
-
Madrid, Španělsko, 28040
- GSK Investigational Site
-
Madrid, Španělsko, 28031
- GSK Investigational Site
-
Marbella, Španělsko, 29603
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Španělsko, 28223
- GSK Investigational Site
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Participant of ≥18 years of age at the time of signing the informed consent or written informed consent is obtained from each study participant's legal guardian.
-
Asthma for ≥ 6 months, defined as:
-
Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023]
-
Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
- Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
- Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines [GINA, 2023], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
- Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines [GINA, 2023] plus SABA, which is anticipated to remain stable for the duration of the study.
- Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
- Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
-
-
Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)
-
Asthma Control Status
-
Asthma Control Questionnaire (ACQ) 6 score <1.5 at screening
-
Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
- Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
- An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
-
-
Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.
-
Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
-
With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
-
Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
- SABA should be withheld for ≥6 hours
- Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
-
Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
-
Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
- SABA should be withheld for ≥6 hours
- LABA- and LAMA-containing medications should be withheld for >=24 hours for the characterization of post-bronchodilator change.
-
Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
Exclusion Criteria:
- A history of life-threatening asthma or asthma that is unstable in the opinion of the investigator.
- Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
- Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
- Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Salbutamol HFA-152a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 μg (ex-valve) at 30-second intervals per actuation |
|
Aktivní komparátor: Salbutamol HFA-134a MDI
Participants with asthma received inhalation of 200 microgram (ug) (2*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 & 12 and a Follow-up visit at Week 13. |
100 microgram (μg) (ex-valve) at 30-second intervals per actuation |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With Adverse Events (AEs) During Run-in Period
Časové okno: From Week -1 up to randomization (Day 1) during Run-in period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Adverse Events (AEs) During Treatment Period
Časové okno: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
Časové okno: From Week -1 up to randomization (Day 1) during Run-in period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From Week -1 up to randomization (Day 1) during Run-in period
|
|
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
Časové okno: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system. |
From randomization (Day 1) up to Week 13 (Follow up) during treatment period
|
|
Absolute Values of Minimum Serum Potassium
Časové okno: Up to Week 13 (Follow up)
|
Blood samples were collected to analyze minimum serum potassium. |
Up to Week 13 (Follow up)
|
|
Absolute Values of Serum Potassium at Each Assessed Visit
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Erythrocytes
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Erythrocytes
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCV
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: MCH
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Hematology Parameter: Hematocrit
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Hematology Parameter: Hematocrit
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Value of Urinalysis Parameter: Specific Gravity
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline of Urinalysis Parameter: Specific Gravity
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
Časové okno: Up to Week 13 (Follow up)
|
Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE & Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL & hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result. |
Up to Week 13 (Follow up)
|
|
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Vital Signs: Pulse Rate
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Vital Signs: Pulse Rate
Časové okno: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
Časové okno: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline for 12 Lead ECGs in QTcF
Časové okno: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Absolute Values for Heart Rate
Časové okno: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Heart Rate
Časové okno: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
|
|
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
Časové okno: Baseline (Day 1, pre-dose) and Week 12
|
The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
|
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Časové okno: Baseline (Day 1, pre-dose) and Week 12
|
Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. |
Baseline (Day 1, pre-dose) and Week 12
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: GSK Clinical Trials, GlaxoSmithKline
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 220735
- 2023-509001-76-00 (Jiný identifikátor: EU CT Number)
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Časový rámec sdílení IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Kritéria přístupu pro sdílení IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .